A one-character carton typo shows how MHRA grades low-risk packaging defects

What happened

On 12 November 2026 the MHRA issued a Class 4 medicines defect notification for Star Pharmaceuticals' enalapril maleate/hydrochlorothiazide 20 mg/12.5 mg tablets. A typographical error on the front of the carton gives the hydrochlorothiazide strength as "12. mg" rather than 12.5 mg. The MHRA states that the tablets themselves are unaffected and that supply should continue.

The record does not say how the error arose, which batches carry it, or whether Star Pharmaceuticals plans to correct the artwork and by when. It also does not say whether the same error appears on other labelling components, such as the leaflet or the blister or container label. Teams should check the full notice for those details before acting.

Why a Class 4 notice still matters

Class 4 is the lowest tier in the MHRA's defect classification. It is generally used where a defect is unlikely to harm patients, and it typically calls for awareness rather than recall or quarantine. The notice says as much: continue to supply.

The defect is still a labelling error in a strength statement, which is one of the most safety-critical pieces of information on a pack. The partial figure "12. mg" is not a plausible alternative strength, and the notice says the tablets are fine. That is presumably why the MHRA graded it as low risk. For a combination product, though, the strength of each active substance is exactly what a pharmacist or prescriber checks against the prescription. A malformed figure creates avoidable queries at the dispensing counter, even if it does not lead to a wrong-strength error.

The quality-system angle

A one-character error on printed packaging usually points to a gap in artwork or proofreading controls rather than a manufacturing fault. The record does not identify the cause, so it would be wrong to speculate about Star Pharmaceuticals' processes. For other marketing authorisation holders and packers, the case raises practical questions:

First, does your artwork approval process include a character-level check of strength statements against the approved product information, not only a visual sign-off? Second, are decimal values and combination-product strengths covered by a second-person verification step? Third, are printed-component checks at goods receipt or line clearance designed to catch typographical errors, or only wrong-product and wrong-batch errors?

A further question is whether your deviation and complaint procedures can quickly separate a labelling defect that leaves the product unaffected from one that touches product quality. The MHRA's wording here, that the tablets are unaffected, is the kind of conclusion a defect assessment should be able to document.

Contrast with recalls elsewhere

Other regulators' notices from the same 24 hours show the other end of the spectrum. Health Canada listed a Type II recall of Beaver-Visitec Mini Blades after an intermittent "open seal" condition meant sterility could not be guaranteed. It also listed a Type I recall of nine Cardinal Health General Procedure Tray configurations after Becton Dickinson asked for discontinuation of infusion sets used with the BD Alaris pump module model 8100. Germany's BfArM published an urgent field safety notice from PTW Freiburg on its Track-it radiotherapy treatment planning software; the specifics sit in the manufacturer's attached advisory.

These are medical devices, not medicines, and the classification systems differ, so they should not be compared directly. They do show the range that quality teams must triage. Some defects mean a product cannot be used or its performance cannot be assured. Others, like the enalapril/hydrochlorothiazide carton, are presentational and carry no product-quality consequence. Getting the classification right avoids both over-reaction and complacency.

Who is affected and what to watch

Directly affected are Star Pharmaceuticals, UK wholesalers and pharmacies holding the product, and anyone who relies on the carton text for stock checks. Because the MHRA says supply should continue, no shortage is implied by the record.

Watch for any follow-up from the company or the MHRA, such as corrected packaging, an update to the notice, or a similar defect found in other presentations. The same day's US enforcement news is a separate matter. HHS OIG listed settlements and charges involving Quest Diagnostics, Lab Genomics LLC and others, and a new Delaware task force on program fraud. Those cases concern healthcare billing and kickbacks, not product quality, and the records do not link them to the MHRA notice. They do show a busy enforcement environment in the US, which is a reminder that compliance functions are being watched on several fronts at once.